Return to homepagePandemic Pact

Comparing Treatments for Patients with Inflammatory Bowel Disease Who Don't Respond to Anti-TNF Therapy

  • Funded by Patient-Centered Outcomes Research Institute
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $359,205

  • Funder

    Patient-Centered Outcomes Research Institute

  • Principal Investigator

    MD. Michael Kappelman

  • Research Location

    United States of America

  • Lead Research Institution

    The University of North Carolina at Chapel Hill

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

People taking medicines for IBD may have a higher risk of infection with COVID-19. If infected, people may also have a higher risk of severe COVID-19. Severe COVID-19 can lead to a hospital stay, breathing support by machine, and even death. With this enhancement, the research team wants to learn how different types of medicines for IBD affect the risk of: Hospitalization due to COVID-19 infection Serious complications or death due to COVID-19 infection The study will take into account patient traits, such as age, other health problems, and whether patients take other medicines known to increase the risk of COVID-19.